Research overview
Retatrutide and tirzepatide with cagrilintide: incretin blends in research
14 November 2026 · 5 min read
Why research combines several pathways at once
Most work on metabolic regulation is built on single peptides. A team compares one compound with a control group and draws conclusions about its effect. Blends, in which several signals act in parallel, are used more often now, because hormones rarely work alone in the body.
Two blends in our range follow the same idea. Retatrutide with cagrilintide and tirzepatide with cagrilintide are research reagents in which an incretin analogue and an amylin analogue sit together in a single vial. The research question is always the same: do signals passed through different receptors strengthen one another, overlap, or act independently?
Incretins: GLP-1, GIP and glucagon in models
Incretins are a group of peptide hormones released from the digestive tract after a meal. The best described in the literature are GLP-1 and GIP. In vitro and in animal models, activation of GLP-1 receptors has been linked to insulin signalling, while GIP receptors complete the picture in a way that is still under study.
The third element of this system is glucagon, a hormone that acts opposite to insulin and appears in the literature in the context of energy handling in the liver and adipose tissue. Retatrutide is described as a molecule that engages all three of these receptors, which is why it is called a triple agonist. Tirzepatide activates the GIP and GLP-1 receptors, so it is a dual agonist.
Amylin and cagrilintide: a third signalling pathway
Amylin is a peptide secreted together with insulin. Research discusses its role in gastric emptying and in the satiety signals sent to the central nervous system. Cagrilintide is an amylin analogue with a fatty acid chain attached. In the literature, adding such a chain is described as a way of prolonging the activity of a peptide in models.
Pairing cagrilintide with incretins makes sense methodologically. Incretins and amylin influence overlapping regulatory processes, so a single experiment can test whether their combined effect differs from the sum of separate observations. Such a design, however, requires clearly defined control groups, including groups that contain each component alone.
In practice the biggest challenge is not the purchase but planning the experimental layout. When two peptides share one vial, it is easy to miss which changes come from the incretin part and which from cagrilintide. For that reason a project is best built on several arms: a control, the incretin component alone, the amylin analogue alone and the full blend. Only by comparing these four groups can you judge whether the combination produces a result different from the sum of the separate observations.
Retatrutide and tirzepatide: two receptor profiles
Both products share cagrilintide but differ in their incretin part. The table below summarises the main features of the two blends, based on the product pages.
| Feature | Retatrutide + cagrilintide | Tirzepatide + cagrilintide |
|---|---|---|
| Receptors described in research | GIP, GLP-1, glucagon and the amylin receptor | GIP, GLP-1 and the amylin receptor |
| Type of incretin component | triple agonist | dual agonist |
| Structure of the incretin component | synthetic peptide, mass 4731.3 g/mol | peptide with 39 amino acids and a C20 fatty acid chain |
| Available variants | 5 mg + 5 mg and 10 mg + 10 mg | 10 mg + 10 mg |
| Form and purity | lyophilisate, ≥ 99% (HPLC) | lyophilisate, ≥ 99% (HPLC) |
The extra glucagon signal in retatrutide means that a comparison with tirzepatide only makes sense when both materials are tested in the same model and under the same conditions. It is also worth remembering that tirzepatide has been studied clinically, and data from those programmes do not describe the use of a laboratory reagent. Both blends follow the same two-part working logic, so the procedures described below apply to both. They differ in molecular mass and in the structure of the incretin component, so concentrations must always be calculated separately for each product.
Working with a two-component lyophilisate
A blend in one vial means one reconstitution but two masses to track. Both components enter the solution in the same proportion, so each one has to be recorded separately in the research log. When calculating working concentrations, use the concentration calculator for each component separately, with the molar mass given on the product page.
Store the lyophilisate at -20 °C, tightly closed and protected from light. Before opening a vial, let it reach room temperature to limit condensation on the dry material. Reconstitution should be carried out in the laboratory according to the protocol. Sterile bacteriostatic water is the most common choice. For tirzepatide with cagrilintide, a diluted acetic acid solution is also sometimes used when a specific protocol calls for it.
Store the ready solution at 2-8 °C. Avoid repeated freezing and thawing, because repeated temperature changes reduce the stability of both peptides. Divide the solution into aliquots and label each one with the reconstitution date, the batch number and the concentration calculated for each component.
For the same reason, keep a reconstitution log. Each entry should include the date, the batch number, the volume of solvent used, the concentrations calculated for both components and the storage conditions from the moment of reconstitution to the last sample withdrawn. Data from such a log make it possible to establish later whether a difference in results comes from the reagent, from the preparation of the solution or from the experiment itself.
Batch quality and shipping
Every batch is tested by HPLC, which confirms a purity of at least 99%. Mass spectrometry (MS) confirms the mass of both components in the blend, so experimental data refer to a specific, identified material. You can read more about our procedures on the quality page.
Orders are dispatched within 24 hours. In Poland the parcel goes to an InPost parcel locker, and for other European countries we ship by DPD courier.
Working in the lab: a plan for the first experiment
Start with a clear research question and define the groups: the incretin component alone, cagrilintide alone and the blend. Only then prepare the solution and record all calculations. Store the lyophilisate at -20 °C, reconstitute it according to the protocol just before use, and keep the solution at 2-8 °C without repeated freezing. Calculate the concentration of each component in the calculator and record it next to the date and batch number. This order keeps results reproducible and makes comparisons between groups meaningful.